| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
α-Pyridone is classified as a human endogenous metabolite. It may interact with various metabolic pathways and enzymes involved in pyridine metabolism. As a plant metabolite, it is involved in secondary metabolism in species such as Perilla frutescens and Lotus burttii. |
|---|---|
| ln Vitro |
In vitro, α-pyridone is used in studies of pyridine metabolism and as a reference standard for analytical chemistry. Its tautomeric forms (2-pyridone and 2-hydroxypyridine) exhibit different chemical properties and reactivities. The compound is also used in the synthesis of various heterocyclic compounds and as a building block in organic chemistry.
|
| ln Vivo |
In vivo, α-pyridone is produced endogenously and excreted in urine. Its role as a metabolite suggests involvement in normal physiological processes. As a plant metabolite, it contributes to the chemical defense and signaling mechanisms of plants. Comprehensive in vivo studies of its pharmacological effects are limited.
|
| Enzyme Assay |
In vitro enzyme assays for α-pyridone typically involve studying enzymes that metabolize pyridine derivatives, such as pyridine hydroxylases or dehydrogenases. The compound is used as a substrate or product to measure enzyme activity. Assays are performed using isolated enzymes or tissue homogenates, and the reaction products are analyzed by chromatographic or spectroscopic methods.
|
| Cell Assay |
In vitro cell experiments with α-pyridone are not extensively documented. The compound may be used in cell culture studies to investigate the metabolism of pyridine derivatives or to assess the cytotoxicity of related compounds. Its role as an endogenous metabolite suggests that it is produced and metabolized by cells under normal physiological conditions.
|
| Animal Protocol |
In vivo animal experiments with α-pyridone are not well-characterized. As an endogenous metabolite, it is present in biological fluids and tissues. Studies on pyridine metabolism in animal models may involve administering pyridine or related compounds and measuring the levels of α-pyridone and other metabolites to assess metabolic pathways and enzyme activities.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for α-pyridone are limited. As a small, polar molecule, it is expected to be readily absorbed and distributed in the body. It is excreted in urine as a metabolite. The compound has a logP of -0.58, indicating moderate hydrophilicity. It is soluble in DMSO at concentrations up to 100 mg/mL and has a melting point of 105-107°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for α-pyridone are limited. As an endogenous metabolite, it is generally considered to have low toxicity. However, high concentrations of pyridine derivatives may be toxic. The compound is intended for research use only and not for human consumption. No comprehensive toxicological studies have been reported.
|
| Additional Infomation |
2-Pyridine-2-ol is a monohydroxypyridine, meaning that pyridine is substituted with a hydroxyl group at the 2-position. It is a plant metabolite. It has been reported that 2-hydroxypyridine is found in perilla, spider lily, and other organisms with relevant data.
α-Pyridone is a research chemical with applications in organic synthesis, analytical chemistry, and metabolomics. It serves as a reference standard for the identification and quantification of pyridine metabolites in biological samples. No clinical trials or approved therapeutic indications exist for this compound. Its mechanism of action is related to its role as a metabolite in pyridine metabolism and plant secondary metabolism. |
| Molecular Formula |
C5H5NO
|
|---|---|
| Molecular Weight |
95.10
|
| Exact Mass |
95.037
|
| CAS # |
142-08-5
|
| PubChem CID |
8871
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
323.7±15.0 °C at 760 mmHg
|
| Melting Point |
107.8 °C
|
| Flash Point |
181.1±5.3 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.514
|
| LogP |
-0.58
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
135
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=O)NC=C1
|
| InChi Key |
UBQKCCHYAOITMY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H5NO/c7-5-3-1-2-4-6-5/h1-4H,(H,6,7)
|
| Chemical Name |
1H-pyridin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (1051.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (26.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (26.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 10.5152 mL | 52.5762 mL | 105.1525 mL | |
| 5 mM | 2.1030 mL | 10.5152 mL | 21.0305 mL | |
| 10 mM | 1.0515 mL | 5.2576 mL | 10.5152 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
